Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377320 | 0.81 | RXFP1 (0.36) | RXFP1LMNATSHRNPSR1SMN1; SMN2 | |
| SCHEMBL21956885 | 0.78 | RXFP1 (0.35) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL13377365 | 0.78 | RXFP1 (0.40) | RXFP1LMNATSHRNPSR1HTT | |
| SCHEMBL22017353 | 0.76 | POLB (0.35) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL28591800 | 0.75 | MAPT (0.38) | RXFP1TDP1LMNATSHRNPSR1 | |
| SCHEMBL23847338 | 0.69 | MAPT (0.33) | TDP1 | |
| SCHEMBL16381205 | 0.66 | RAB9A (0.38) | LMNANPSR1HTTRAB9ACYP1A2 | |
| SCHEMBL22035529 | 0.66 | KDM5B (0.31) | — | |
| SCHEMBL13377306 | 0.65 | RXFP1 (0.33) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL21957120 | 0.65 | AR (0.41) | RXFP1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | RXFP1 2319/4885TDP1 2395/4885LMNA 2900/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | RXFP1 2319/4885TDP1 2395/4885LMNA 2900/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | RXFP1 2319/4885TDP1 2395/4885LMNA 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.